- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02171559
Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers
June 20, 2014 updated by: Boehringer Ingelheim
Relative Bioavailability and Pharmacodynamics of Dabigatran After a Single Dose of 220 mg Dabigatran Etexilate and After 40 mg Enoxaparin s.c. for 3 Days Followed by a Single Dose of 220 mg Dabigatran Etexilate in Healthy Male and Female Volunteers (an Open-label, Randomised, Single and Multiple Dose, Two Way Crossover Phase I Study)
To investigate the relative bioavailability and the pharmacodynamics of dabigatran after switching from enoxaparin to dabigatran etexilate as compared to dabigatran etexilate alone
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects were healthy males and females based upon a complete medical history, including a physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG, and clinical laboratory tests
- Age ≥18 to ≤55 years
- Body mass index (BMI) ≥18.5 to ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
Exclusion Criteria:
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
- Relevant surgery of gastrointestinal tract
- History of any bleeding disorder or acute blood coagulation defect
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator
- Intake of any medication within 2 weeks of first dosing, especially intake of medication, which influences blood clotting, i.e. acetylsalicylic acid, cumarin etc.
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 4 weeks prior to administration or during the trial
- Alcohol abuse (more than 60 g/day for males and more than 20 g/day for females)
- Drug abuse
- Intake of grapefruit, grapefruit juice, or products containing grapefruit juice, Seville oranges, garlic supplements, or St. John's wort within 5 days of first dosing
- Participation in another trial with an investigational drug within 2 months prior to trial drug administration or during the trial
- Blood donation (more than 100 mL within 4 weeks prior to trial drug administration or during the trial)
- Excessive physical activities (within 1 week prior to trial drug administration or during the trial)
- Any laboratory value outside the reference range that was of clinical relevance
- Inability to comply with dietary regimen of study centre
- Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
Inability to refrain from smoking on trial days
For female subjects:
- Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month after study completion
- No adequate contraception during the study and within 1 month after study completion such as implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who did not have a vasectomised partner, were not sexually abstinent or surgically sterile, were asked to additionally use a barrier contraception method (e.g. condom, diaphragm with spermicide)
- Lactation period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dabigatran etexilate capsules after enoxaparin ampoules
|
|
Active Comparator: Dabigatran etexilate capsules without enoxaparin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Maximum measured concentration of the analyte in plasma (Cmax ) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Area under the effect-time curve of the analyte in plasma over the time interval from 0 to 48 h after administration (AUEC0-48) after dabigatran alone and after dabigatran following enoxaparin administration
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Maximum effect ratio to baseline (ERmax) after dabigatran alone and after dabigatran following enoxaparin administration
Time Frame: Baseline and up to 48 hours after drug administration
|
Baseline and up to 48 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Time from dosing to the maximum concentration of the analyte in plasma (tmax) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Terminal rate constant in plasma (λz) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Terminal half-life of the analyte in plasma (t1/2) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Mean residence time of the analyte in the body after oral administration (MRTpo) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Apparent clearance of the analyte in plasma after extravascular administration (CL/F) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Apparent volume of distribution during the terminal phase λz following an extravascular administration (Vz/F) of dabigatran
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Anti-FIIa activity for Dabigatran etexilate
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Anti-FXa/anti-FIIa activity for Enoxaparin
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Activated partial thromboplastin time (aPTT) for Dabigatran etexilate
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Ecarin clotting time (ECT) for Dabigatran etexilate
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Thrombin time (TT) for Dabigatran etexilate
Time Frame: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Change in vital signs (blood pressure, pulse rate)
Time Frame: up to day 61
|
up to day 61
|
Change in 12-lead electrocardiogram (ECG)
Time Frame: up to day 61
|
up to day 61
|
Change in clinical laboratory tests
Time Frame: up to day 61
|
up to day 61
|
Occurrence of adverse events
Time Frame: Up to day 61
|
Up to day 61
|
Assessment of global tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)
Time Frame: Day 61
|
Day 61
|
Assessment of local tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)
Time Frame: day 3 of enoxaparin administration
|
day 3 of enoxaparin administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
September 1, 2008
Study Registration Dates
First Submitted
June 20, 2014
First Submitted That Met QC Criteria
June 20, 2014
First Posted (Estimate)
June 24, 2014
Study Record Updates
Last Update Posted (Estimate)
June 24, 2014
Last Update Submitted That Met QC Criteria
June 20, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1160.78
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Dabigatran etexilate capsules
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedVenous Thrombosis | Arthroplasty, Replacement, KneeJapan
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Nova Scotia Health AuthorityDalhousie University; Université de Montréal; Capital Health, CanadaCompletedBlood Coagulation DisordersCanada
-
Boehringer IngelheimCompleted